Overview
Quotient Therapeutics and Pioneering Medicines, Flagship Pioneering's internal drug development unit, have embarked on a collaborative research initiative aimed at identifying somatic mutations in genes that influence the progression of cardiovascular and renal diseases.
Strategic Partnership: Flagship Pioneering & Pfizer
- This collaboration, part of the ongoing strategic partnership between Flagship Pioneering and Pfizer, will leverage Quotient's Somatic Genomics platform to explore genetic diversity within diseased patient tissue.
- The insights gained from this analysis are expected to inform the discovery and development of new therapies targeting these conditions.
Terms of the Partnership
- Under the terms of the partnership, Pioneering Medicines will lead the research efforts with Quotient, building on the strategic alliance established between Flagship and Pfizer in July 2023.
- The joint research programs with Quotient mark a significant step forward in this collaboration, which is focused on accelerating the development of innovative drug therapies.
Opportunity to utilize Quotient's Platform
- The strategic collaboration provides an opportunity to utilize Quotient's proprietary platform in early discovery work, potentially unveiling new targets for addressing cardiovascular and renal diseases.
- By combining Flagship's bioplatforms with Pfizer's expertise in cardiometabolic research, the partnership aims to address critical gaps in patient care and accelerate therapeutic innovation.
